BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 31468288)

  • 1. Game of thrones: immunotherapy versus molecular targeted therapy in renal cell cancer scenarios.
    Cetin B; Kosar A
    Int Urol Nephrol; 2019 Dec; 51(12):2107-2117. PubMed ID: 31468288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions.
    Lalani AA; McGregor BA; Albiges L; Choueiri TK; Motzer R; Powles T; Wood C; Bex A
    Eur Urol; 2019 Jan; 75(1):100-110. PubMed ID: 30327274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
    Calvo E; Porta C; Grünwald V; Escudier B
    Oncologist; 2019 Mar; 24(3):338-348. PubMed ID: 30158285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials.
    Godwin JL; Zibelman M; Plimack ER; Geynisman DM
    Discov Med; 2014 Dec; 18(101):341-50. PubMed ID: 25549705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
    Zibelman M; Plimack ER
    J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Check point inhibitors a new era in renal cell carcinoma treatment.
    Alsharedi M; Katz H
    Med Oncol; 2018 May; 35(6):85. PubMed ID: 29728867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of immunotherapy in kidney cancer.
    Nazzani S; Bazinet A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
    de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
    Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant Therapy Options in Renal Cell Carcinoma: Where Do We Stand?
    Martinez Chanza N; Tripathi A; Harshman LC
    Curr Treat Options Oncol; 2019 May; 20(5):44. PubMed ID: 31054006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
    Carlo MI; Voss MH; Motzer RJ
    Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant therapy for advanced renal cell carcinoma.
    Meissner MA; McCormick BZ; Karam JA; Wood CG
    Expert Rev Anticancer Ther; 2018 Jul; 18(7):663-671. PubMed ID: 29707987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma.
    Grünwald V
    Oncol Res Treat; 2016; 39(6):353-8. PubMed ID: 27259695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
    Raman R; Vaena D
    Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present and future therapeutic options for locally advanced and metastatic renal cell carcinoma.
    Sfoungaristos S; Giannitsas K; Perimenis P
    Expert Opin Pharmacother; 2011 Mar; 12(4):533-47. PubMed ID: 21306289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
    Liu KG; Gupta S; Goel S
    Oncotarget; 2017 Mar; 8(10):17313-17327. PubMed ID: 28061473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatments, Outcomes, and Validity of Prognostic Scores in Patients With Sarcomatoid Renal Cell Carcinoma: A 20-Year Single-Institution Experience.
    Korenbaum C; Pierard L; Thiéry A; Story F; Lindner V; Lang H; Kurtz JE; Barthélémy P
    Clin Genitourin Cancer; 2018 Jun; 16(3):e577-e586. PubMed ID: 29395949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Obesity in Renal Cell Carcinoma Patients: Clinical-Pathological Implications.
    Aurilio G; Piva F; Santoni M; Cimadamore A; Sorgentoni G; Lopez-Beltran A; Cheng L; Battelli N; Nolè F; Montironi R
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31766196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pazopanib for the treatment of metastatic renal cell carcinoma.
    Pick AM; Nystrom KK
    Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.
    Tenold M; Ravi P; Kumar M; Bowman A; Hammers H; Choueiri TK; Lara PN
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
    Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
    Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.